• F. Duffaud
  • R. Favre


The biphosphonates have a phosphate-carbon-phosphate backbone, which binds tightly to calcified bone matrix. This core structure allows many possible variations by changing side chains or by esterifiyng phosphate groups. Many biphosphonates have been synthesised, with different chemical and biological characteristics.


Breast Cancer Breast Cancer Patient Bone Metastasis Skeletal Metastasis Intravenous Pamidronate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Body JJ (1992) Bone metastases and tumor-induced hypercalcemia. Curr Opin Oncol 4: 624–631.PubMedCrossRefGoogle Scholar
  2. Body JJ, Dumon JC, Piccart M et al (1995) Intravenous pamidronate in patients with tumor induced osteolysis a biochemical dose-response study. J Bone Mineral Res 10: 1191–1196.CrossRefGoogle Scholar
  3. Body JJ, Coleman RE, Piccart M (1996) Use of biphosphonates in cancer patients. Cancer Treatment Reviews 22: 265–287.PubMedCrossRefGoogle Scholar
  4. Coleman RE, Woll PJ, Miles H et al (1998) Treatment of bone metastases from breast cancer with (3-amino-l-hydroxypropylidene)-1,lbiphosphonate ( APD ). Br J Cancer 58: 621–625.Google Scholar
  5. Coleman RE, Vinholes J, Abbey ME (1996) Double-blind randomized trial of pamidronate for the palliative treatment of metastatic bone disease. Proc Am Soc Clin Oncol 15: 528 (Abstract 1506).Google Scholar
  6. Conte PF, Giannessi PG, Latreille J et al (1994) Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomized, multicenter phase III trial. Ann Oncol 5 (suppl 7): S41–44.PubMedGoogle Scholar
  7. Conte PF, Latreille J, Mauriac F et al (1996) Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. J Clin Oncol 14: 2552–2559.PubMedGoogle Scholar
  8. Diel IJ, Solomayer R, Goerner C et al (1997) Adjuvant treatment of breast cancer patients with the biphosphonate clodronate reduces incidence and number of bone and non-bone metastases. Proc Am Soc Clin Oncol 16: 130a (Abstract).Google Scholar
  9. Ernst DS, MacDonald RN, Paterson AHG et al (1992) A double-blind, cross-over trial of IV clodronate in metastatic bone pain. J Pain Symptomatol Management 7: 4–11.CrossRefGoogle Scholar
  10. Hortobagyi GN, Theriault RL, Porter L et al (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 335: 1836–1837.CrossRefGoogle Scholar
  11. Hughes DE, Wright KR, Uy HL et al (1995) Biphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Mineral Res 10: 1478–1487.CrossRefGoogle Scholar
  12. Löwik CWGM, der Pluijm G, van der Wee-Pals et al (1988) Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effects of a biphosphonate. J Bone Mineral Res 2: 185–192.Google Scholar
  13. Morton AR, Canctrill JA, Pillar GV et al. (1988) Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene biphosphonate ( APD) in patients with breast carcinoma. Br Med J 297: 772–773.Google Scholar
  14. Paterson AHG, Powles TJ, Kanis JA et al (1993) Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11: 59–65.PubMedGoogle Scholar
  15. Paterson AHG, McCloskey EV, Ashley S et al (1996) Reduction of skeletal morbidity and prevention of bone marrow metastases with oral clodronate in women with recurrent breast cancer in the absence of skeletal metastases. Proc Am Soc Clin Oncol 15: 104 (Abstract).Google Scholar
  16. Ralston SH (1992) Medical management of hypercalcemia. Br J Clin Pharmacol 34: 11–20.PubMedCrossRefGoogle Scholar
  17. Reitsma PH, Teitelbaum SL, Bijvoet OL et al (1982) Differential action of the biphosphonates (3-amino-l-hydroxypropylene)-1,1-biphosphonate (ADP) and dosodium dichloromethylidene (C12MDP) on rat macrophage-mediated bone resorption in vitro. J Clin Invest 70: 927–933.PubMedCrossRefGoogle Scholar
  18. Robertson AG, Reed NS, Ralston SH (1995) Effect of oral clodronate on metastatic bone pain: a doubleblind, placebo-controlled study. J Clin Oncol 13: 2127–2130.Google Scholar
  19. Sahni M, Guenther HL, Fleisch H et al (1993) Biphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 91: 2004–2011.PubMedCrossRefGoogle Scholar
  20. Theriault R, Lipton A, Leff R et al (1996) Reduction of skeletal complications in breast cancer patients with osteolytic bone metastases receiving hormone therapy by monthly pamidronate sodium (Aredia) infusion. Proc Am Soc Clin Oncol 15: 122 (Abstract).Google Scholar
  21. Thiebaud D, Leyvraz S, von Fliedner V et al (1991) Treatment of bone metastases from breast cancer and myeloma with pamirironate. Eur J Cancer 27: 37–41.PubMedCrossRefGoogle Scholar
  22. Van Holten-Verzantvoort ATM, Bijvoet OLM, Hermans J et al (1987) Reduced morbidity from skeletal metastases in breast cancer patients during long-term biphosphonate (APD) treatment. Lancet ii: 983–985.Google Scholar
  23. Van Holten-Verzantvoort ATM, Kroon HM, Bijvoet OLM et al (1993) Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 11: 491–498.PubMedGoogle Scholar

Copyright information

© Springer-Verlag London 2002

Authors and Affiliations

  • F. Duffaud
  • R. Favre

There are no affiliations available

Personalised recommendations